{"id":51967,"date":"2022-12-14T14:02:22","date_gmt":"2022-12-14T13:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/"},"modified":"2022-12-14T14:02:22","modified_gmt":"2022-12-14T13:02:22","slug":"abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/","title":{"rendered":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis"},"content":{"rendered":"
\n

\nABA-101 aims to benefit a subset of progressive MS patients with no treatment options<\/i>\n<\/p>\n

\nABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024<\/i>\n<\/p>\n

BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has chosen its first development candidate, ABA-101, which has the potential to benefit 45,000 progressive multiple sclerosis (MS) patients in the U.S. who have no treatment options today.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe progressive pathology of MS has not been effectively treated because existing therapies don\u2019t address the CNS-compartmentalized inflammation that drives that aspect of the disease,\u201d said Richard M. Ransohoff, M.D., co-founder and chief medical officer at Abata and venture partner at Third Rock Ventures. \u201cOur approach of leveraging the natural role of Tregs in the immune system enables us to resolve complex inflammatory mechanisms, offering new hope for patients with no treatment options. Our work to date developing ABA-101 validates our approach of using TCR-targeted Treg therapies to treat autoimmune diseases. We look forward to working with our new CSO, Ellen Cahir-McFarland, to translate the science behind ABA-101 into clinical studies in the first half of 2024.\u201d\n<\/p>\n

\n\u201cSince our inception, we\u2019ve been acutely focused on advancing transformative therapies for people with autoimmune diseases. We believe that our Treg product engine has yielded a candidate in ABA-101 that is truly differentiated and can have significant benefit for people living with progressive MS,\u201d said Samantha Singer, M.S., M.B.A., president and chief executive officer of Abata. \u201cABA-101 utilizes a TCR to target our product specifically to the site of ongoing pathology and to offer the potential for a robust, highly durable effect. Working with our partners at ElevateBio BaseCamp, we\u2019ve rapidly established a foundational manufacturing process in less than one year, showing we can successfully engineer and expand Tregs for use as therapies. Overall, this work gives us great confidence not only in our ABA-101 program, but also in our additional programs in type 1 diabetes and inclusion body myositis.\u201d\n<\/p>\n

\n\u201cAt ElevateBio, we enjoy collaborating with scientific innovators like Abata, helping power their novel cell and gene therapies,\u201d said Michael Paglia, M.S., chief operating officer, ElevateBio BaseCamp. \u201cIt\u2019s been a pleasure working with the Abata team creating and refining a manufacturing process that enables them to expand Tregs engineered with an antigen-specific TCR at yields that will support clinical development of ABA-101 and serves as a template for their future programs. We look forward to the continued partnership.\u201d\n<\/p>\n

\nThe hypothesis for ABA-101 as a Treg treatment for progressive MS is firmly rooted in the scientific literature. Single-cell data link chronic active lesions in patients to the adaptive immune system, reinforcing the possibility that a Treg can have a therapeutic effect in progressive MS. Additionally, EAE (experimental autoimmune encephalomyelitis) mouse studies demonstrate <\/b>proof of biology, <\/b>including TCR-Treg trafficking, persistence, biological activity, and suppression of inflammation \u2013 all critical elements for a successful treatment. Additional non-clinical studies establish Tregs\u2019 <\/b>role in myelin repair, a further potential benefit of the approach. Abata will use MRI to select patients for inclusion as clinical trial participants, as chronic active lesions (identifiable with MRI) correlate with worsening disease <\/b>in progressive MS natural history studies.\n<\/p>\n

\nAbout ABA-101 and Progressive Multiple Sclerosis
\n
<\/b>ABA-101 is Abata\u2019s autologous Treg therapy in development for the treatment of progressive MS. It targets MS patients with non-relapsing progressive disease who have a DRB1*15:01 genetic haplotype and for whom imaging evidence of ongoing inflammatory tissue injury has been observed \u2013 an estimated patient group of about 45,000 in the U.S. today. ABA-101 is created by minimally engineering a patient\u2019s own Tregs to express a TCR that specifically recognizes immunogenic myelin fragments in the CNS \u2013 an approach that offers a potentially strong safety profile and a highly localized anti-inflammatory effect at the site of disease. In vitro<\/i>, ABA-101 has demonstrated antigen-specific, dose-dependent Treg functionality, anti-inflammatory cytokine production, and suppression of the production of inflammatory factors (T cell-derived cytokines). ABA-101 also retains its Treg phenotype under inflammatory conditions.\n<\/p>\n

\nAbout Abata Therapeutics
\n
<\/b>Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. In addition to its lead program in progressive MS, Abata has programs in type 1 diabetes and inclusion body myositis \u2013 two other tissue-specific autoimmune diseases with substantial unmet need and a strong rationale for Abata\u2019s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Cambridge, Mass. Please visit abatatx.com<\/a> or follow us on Twitter<\/a> or LinkedIn for more information<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
<\/b>Cory Tromblee
\n
Scient PR
\n
cory@scientpr.com<\/a>\n<\/p>\n

\nInvestor
\n
<\/b>Julie Seidel
\n
Stern Investor Relations, Inc.
\n
julie.seidel@sternir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ABA-101 aims to benefit a subset of progressive MS patients with no treatment options ABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024 BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51967","6":"format-standard","7":"category-industry"},"yoast_head":"\nAbata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ABA-101 aims to benefit a subset of progressive MS patients with no treatment options ABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024 BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-14T13:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis\",\"datePublished\":\"2022-12-14T13:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/\"},\"wordCount\":875,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005205\\\/en\\\/1663894\\\/21\\\/1-primary-large-dark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/\",\"name\":\"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005205\\\/en\\\/1663894\\\/21\\\/1-primary-large-dark.jpg\",\"datePublished\":\"2022-12-14T13:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005205\\\/en\\\/1663894\\\/21\\\/1-primary-large-dark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005205\\\/en\\\/1663894\\\/21\\\/1-primary-large-dark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/","og_locale":"en_US","og_type":"article","og_title":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend","og_description":"ABA-101 aims to benefit a subset of progressive MS patients with no treatment options ABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024 BOSTON–(BUSINESS WIRE)–Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-14T13:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis","datePublished":"2022-12-14T13:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/"},"wordCount":875,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/","url":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/","name":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg","datePublished":"2022-12-14T13:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221214005205\/en\/1663894\/21\/1-primary-large-dark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/abata-therapeutics-announces-first-development-candidate-aba-101-a-novel-treg-cell-therapy-for-the-treatment-of-progressive-multiple-sclerosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51967"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51967\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}